Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Safety Study to Evaluate the Safety and Effectiveness of Epcoritamab in Korean Adult Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

NCT07862764 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07862764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Safety Study to Evaluate the Safety and Effectiveness of Epcoritamab in Korean Adult Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Not yet recruiting
Start date
October 2, 2026
Completion date
November 30, 2029
Enrollment
175 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma